India Proposes Stricter Advertising Curbs for Prescription Medicines
New draft amendment expands drug promotion restrictions to retailers, wholesalers, and distributors.
1Expanding Regulatory Scope
The Union Health Ministry has introduced a draft amendment to the Drugs Rules, 1945, aiming to tighten control over prescription medicine promotion. While manufacturers were already restricted, the new proposal extends these advertising prohibitions to retailers, wholesalers, and distributors. This move seeks to close a significant regulatory gap within the existing pharmaceutical supply chain framework.
2Targeting Specific Schedules
The proposed rules specifically target drugs listed under Schedules H, H1, and X. These categories include potent medications requiring strict medical supervision, such as specific antibiotics and psychotropic drugs. By prohibiting unauthorized promotion of these items, the government intends to curb risks associated with the misuse of prescription medicines and prevent potential patient safety hazards.
3Closing Legal Loopholes
Under current regulations, only pharmaceutical manufacturers face explicit advertising restrictions for these schedules. The draft amendment, notified via Gazette notification G.S.R. 861(E) on September 28, inserts a new sub-rule under Rule 65. This change ensures that all entities involved in the sale, stocking, or distribution of these drugs must obtain prior government sanction before advertising.
4DTAB Strategic Recommendations
This regulatory shift follows formal recommendations from the 93rd meeting of the Drugs Technical Advisory Board held on February 16, 2026. The board evaluated the necessity of regulating advertisements by license holders involved in drug distribution. Their findings highlighted the urgent need to standardize promotional oversight across every tier of the national pharmaceutical market.
5Mitigating Self-Medication Risks
The primary driver behind this policy is the reduction of inappropriate self-medication practices. Unauthorized promotion often encourages patients to bypass professional medical advice, leading to the misuse of critical drugs. By restricting the visibility of these advertisements, the Ministry aims to ensure that medical decisions remain firmly in the hands of qualified healthcare professionals.
6Public Consultation Process
The Ministry has officially invited objections and suggestions from stakeholders and the general public regarding the draft rules. Interested parties have a 30-day window from the date the Gazette notification was made available to submit their feedback. The Central government will review all received submissions before finalizing the amendment and implementing the new legal requirements.
7Supply Chain Compliance
This amendment forces a shift in operational compliance for thousands of small and large-scale drug distributors across India. Entities that previously operated under the assumption that only manufacturers were liable for promotional content must now align their marketing strategies with the new federal oversight. This ensures consistent enforcement across the entire pharmaceutical distribution network.
8Future Regulatory Outlook
The proposed changes represent a tightening of the pharmaceutical landscape, prioritizing public health over commercial promotional freedom. By integrating retailers and wholesalers into the regulatory net, the government is signaling a more proactive stance on drug safety. Future enforcement will likely focus on monitoring digital and physical marketing channels to ensure full compliance with these updated standards.